[go: up one dir, main page]

WO2006096497A3 - Compositions contenant des molecules conjuguees structurellement stables - Google Patents

Compositions contenant des molecules conjuguees structurellement stables Download PDF

Info

Publication number
WO2006096497A3
WO2006096497A3 PCT/US2006/007571 US2006007571W WO2006096497A3 WO 2006096497 A3 WO2006096497 A3 WO 2006096497A3 US 2006007571 W US2006007571 W US 2006007571W WO 2006096497 A3 WO2006096497 A3 WO 2006096497A3
Authority
WO
WIPO (PCT)
Prior art keywords
iss
vaccines
oligonucleotides
antigens
conjugated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2006/007571
Other languages
English (en)
Other versions
WO2006096497A2 (fr
Inventor
Stephen F Tuck
Roberto Rodriguez
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dynavax Technologies Corp
Original Assignee
Dynavax Technologies Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dynavax Technologies Corp filed Critical Dynavax Technologies Corp
Priority to CA002600036A priority Critical patent/CA2600036A1/fr
Priority to AU2006220835A priority patent/AU2006220835B2/en
Priority to JP2007558260A priority patent/JP2008531722A/ja
Priority to NZ561144A priority patent/NZ561144A/en
Priority to EP06736828A priority patent/EP2007421A2/fr
Publication of WO2006096497A2 publication Critical patent/WO2006096497A2/fr
Publication of WO2006096497A3 publication Critical patent/WO2006096497A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/35—Allergens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/35—Allergens
    • A61K39/36—Allergens from pollen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6006—Cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6025—Nucleotides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

L'invention concerne des compositions contenant des molécules conjuguées structurellement stables à une température comprise entre environ 2 et 8 degrés C. dans certains modes de réalisation, la molécule conjuguée contient un antigène, tel qu'un allergène. Dans d'autres modes de réalisation, une molécule conjuguée contient un antigène Amb d'herbe à poux à 1°. Cette invention concerne également des procédé destinés à fabriquer et à utiliser ces compositions, ainsi que des procédés de modulation d'une réponse immunitaire chez un individu qui consiste à administrer une composition contenant une molécule conjuguée structurellement stable telle que décrite dans cette invention.
PCT/US2006/007571 2005-03-04 2006-03-03 Compositions contenant des molecules conjuguees structurellement stables Ceased WO2006096497A2 (fr)

Priority Applications (5)

Application Number Priority Date Filing Date Title
CA002600036A CA2600036A1 (fr) 2005-03-04 2006-03-03 Compositions contenant des molecules conjuguees structurellement stables
AU2006220835A AU2006220835B2 (en) 2005-03-04 2006-03-03 Vaccines comprising oligonucleotides having immunostimulatory sequences (ISS) wherein the ISS are conjugated to antigens and stabilized by buffer conditions and further excipients
JP2007558260A JP2008531722A (ja) 2005-03-04 2006-03-03 構造的に安定なコンジュゲート分子を含む組成物
NZ561144A NZ561144A (en) 2005-03-04 2006-03-03 Vaccines comprising oligonucleotides having immunostimulatory sequences (ISS) wherein the ISS are conjugated to antigens and stabilized by buffer conditions and further excipients
EP06736828A EP2007421A2 (fr) 2005-03-04 2006-03-03 Vaccins comprenant des oligonucleotides immunostimulateurs (iss), desquels iss sont conjugues a des antigenes et stabilises dans des conditions de tampon et par d'autres excipients

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US65894705P 2005-03-04 2005-03-04
US60/658,947 2005-03-04

Publications (2)

Publication Number Publication Date
WO2006096497A2 WO2006096497A2 (fr) 2006-09-14
WO2006096497A3 true WO2006096497A3 (fr) 2007-05-03

Family

ID=36953874

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/007571 Ceased WO2006096497A2 (fr) 2005-03-04 2006-03-03 Compositions contenant des molecules conjuguees structurellement stables

Country Status (10)

Country Link
US (2) US7718622B2 (fr)
EP (1) EP2007421A2 (fr)
JP (1) JP2008531722A (fr)
KR (1) KR20070110901A (fr)
CN (1) CN101171033A (fr)
AU (1) AU2006220835B2 (fr)
CA (1) CA2600036A1 (fr)
NZ (1) NZ561144A (fr)
SG (1) SG160336A1 (fr)
WO (1) WO2006096497A2 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8252757B2 (en) 2006-11-09 2012-08-28 Dynavax Technologies Corporation Long term disease modification using immunostimulatory oligonucleotides
US8815817B2 (en) 2008-05-15 2014-08-26 Dynavax Technologies Corporation Long term disease modification using immunostimulatory oligonucleotides
USRE45196E1 (en) 2005-03-04 2014-10-14 Dynavax Technologies Corporation Compositions comprising structurally stable conjugate molecules

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7935675B1 (en) 1994-07-15 2011-05-03 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US7585847B2 (en) 2000-02-03 2009-09-08 Coley Pharmaceutical Group, Inc. Immunostimulatory nucleic acids for the treatment of asthma and allergy
WO2003000922A2 (fr) * 2001-06-21 2003-01-03 Dynavax Technologies Corporation Composes immunomodulateurs chimeriques et leurs procedes d'utilisation
KR20050052467A (ko) * 2002-08-12 2005-06-02 다이나박스 테크놀로지 코퍼레이션 면역조절 조성물, 이의 제조방법 및 이의 이용방법
US8158768B2 (en) 2002-12-23 2012-04-17 Dynavax Technologies Corporation Immunostimulatory sequence oligonucleotides and methods of using the same
DK2153841T4 (en) * 2008-08-15 2016-02-15 Circassia Ltd Vaccine comprising Amb a 1 peptides for use in the treatment of ambrosieallergi
GB0821806D0 (en) * 2008-11-28 2009-01-07 Circassia Ltd Compositions with reduced dimer formation
US20100233270A1 (en) 2009-01-08 2010-09-16 Northwestern University Delivery of Oligonucleotide-Functionalized Nanoparticles
DE102009034779A1 (de) 2009-07-25 2011-02-03 Emc Microcollections Gmbh Synthetische Analoga bakterieller Lipopeptide und ihre Anwendung zur Therapie und Prophylaxe allergischer Erkrankungen
CA2919268C (fr) 2013-07-25 2023-09-05 Exicure, Inc. Constructions a partir d'acides nucleiques spheriques utilisees en tant qu'agents immunostimulants a des fins prophylactiques et therapeutiques
WO2015187966A1 (fr) 2014-06-04 2015-12-10 Aurasense Therapeutics, Llc Libération polyvalente de modulateurs immunitaires par des acides nucléiques sphériques liposomaux pour des applications prophylactiques ou thérapeutiques
CN104181309B (zh) * 2014-08-22 2016-03-02 山东博科生物产业有限公司 一种灵敏度高的肌钙蛋白i检测试剂盒
CN107106493A (zh) 2014-11-21 2017-08-29 西北大学 球形核酸纳米颗粒缀合物的序列特异性细胞摄取
US11364304B2 (en) 2016-08-25 2022-06-21 Northwestern University Crosslinked micellar spherical nucleic acids
EP3295956A1 (fr) 2016-09-20 2018-03-21 Biomay Ag Construction de polypeptide comprenant des fragments d'allergenes
US12364745B2 (en) * 2022-06-30 2025-07-22 Dynavax Technologies Corporation Immunogenicity of a CpG-adjuvanted recombinant plague vaccine

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001015726A2 (fr) * 1999-08-27 2001-03-08 Inex Pharmaceuticals Corp. Compositions stimulant la secretion de cytokine et provoquant une reaction immunitaire
WO2001035991A2 (fr) * 1999-11-15 2001-05-25 Dynavax Technologies Corporation Compositions immunomodulatrices contenant une sequence immunostimulante liee a un antigene et procedes d'utilisation
US6251678B1 (en) * 1999-02-05 2001-06-26 Merck & Co., Inc. Human papillomavirus vaccine formulations
WO2003000922A2 (fr) * 2001-06-21 2003-01-03 Dynavax Technologies Corporation Composes immunomodulateurs chimeriques et leurs procedes d'utilisation
WO2003106644A2 (fr) * 2002-06-14 2003-12-24 Medimmune, Inc. Formulations d'anticorps anti-virus syncytial respiratoire (rsv) stabilisees
WO2004060396A2 (fr) * 2002-12-27 2004-07-22 Chiron Corporation Immunogenes contenant des compositions de phospholipide

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4705684A (en) 1985-05-31 1987-11-10 The University Of Tennessee Research Corporation Synthetic M proteins - streptococci type 6
US5985847A (en) * 1993-08-26 1999-11-16 The Regents Of The University Of California Devices for administration of naked polynucleotides which encode biologically active peptides
WO1995005853A1 (fr) 1993-08-26 1995-03-02 The Regents Of The University Of California Procede, compositions et dispositifs pour l'administration de polynucleotides nus qui codent des peptides a activite biologique
US5849719A (en) * 1993-08-26 1998-12-15 The Regents Of The University Of California Method for treating allergic lung disease
US5679647A (en) * 1993-08-26 1997-10-21 The Regents Of The University Of California Methods and devices for immunizing a host against tumor-associated antigens through administration of naked polynucleotides which encode tumor-associated antigenic peptides
US5804566A (en) * 1993-08-26 1998-09-08 The Regents Of The University Of California Methods and devices for immunizing a host through administration of naked polynucleotides with encode allergenic peptides
US5830877A (en) * 1993-08-26 1998-11-03 The Regents Of The University Of California Method, compositions and devices for administration of naked polynucleotides which encode antigens and immunostimulatory
US6270757B1 (en) * 1994-04-21 2001-08-07 Genetics Institute, Inc. Formulations for IL-11
US6207646B1 (en) * 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US7935675B1 (en) * 1994-07-15 2011-05-03 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US5843943A (en) * 1994-12-29 1998-12-01 The Regents Of The University Of California Compounds for inhibition of ceramide-mediated signal transduction
US6323201B1 (en) * 1994-12-29 2001-11-27 The Regents Of The University Of California Compounds for inhibition of ceramide-mediated signal transduction
US5656730A (en) * 1995-04-07 1997-08-12 Enzon, Inc. Stabilized monomeric protein compositions
US6685940B2 (en) * 1995-07-27 2004-02-03 Genentech, Inc. Protein formulation
JP4359654B2 (ja) 1996-01-30 2009-11-04 ザ リージェンツ オブ ザ ユニバーシティー オブ カリフォルニア 抗原特異的免疫応答を生起させる遺伝子発現ベクターおよびその使用方法
US5763401A (en) * 1996-07-12 1998-06-09 Bayer Corporation Stabilized albumin-free recombinant factor VIII preparation having a low sugar content
EP0930893B1 (fr) * 1996-10-11 2005-04-13 The Regents of The University of California Conjugues polynucleotide immunostimulateur/molecule immunomodulatrice
US6797276B1 (en) * 1996-11-14 2004-09-28 The United States Of America As Represented By The Secretary Of The Army Use of penetration enhancers and barrier disruption agents to enhance the transcutaneous immune response
US6406705B1 (en) * 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
DK1003850T3 (da) * 1997-06-06 2009-09-07 Univ California Inhibitorer af DNA-immunstimulatorisk sekvensaktivitet
US20040006034A1 (en) * 1998-06-05 2004-01-08 Eyal Raz Immunostimulatory oligonucleotides, compositions thereof and methods of use thereof
US6589940B1 (en) * 1997-06-06 2003-07-08 Dynavax Technologies Corporation Immunostimulatory oligonucleotides, compositions thereof and methods of use thereof
WO1999011275A2 (fr) * 1997-09-05 1999-03-11 The Regents Of The University Of California Utilisation d'oligonucleotides immunostimulants pour la prevention ou la reduction des inflammations a mediation granulocytaire et stimulees par des antigenes
US6562798B1 (en) 1998-06-05 2003-05-13 Dynavax Technologies Corp. Immunostimulatory oligonucleotides with modified bases and methods of use thereof
DE69931377T2 (de) * 1998-09-18 2007-05-10 Dynavax Technologies Corp., Berkeley Verfahren zur behandlung von ig-e assozierten krankheiten und zusammensetzungen zur verwendung in diesen verfahren
CA2344558A1 (fr) 1998-10-09 2000-04-20 Dynavax Technologies Corporation Compositions anti-hiv comprenant des polynucleotides immunostimulants et des antigenes hiv
US6689600B1 (en) * 1998-11-16 2004-02-10 Introgen Therapeutics, Inc. Formulation of adenovirus for gene therapy
FR2790955B1 (fr) * 1999-03-19 2003-01-17 Assist Publ Hopitaux De Paris Utilisation d'oligonucleotides stabilises comme principe actif antitumoral
US6737066B1 (en) * 1999-05-06 2004-05-18 The Immune Response Corporation HIV immunogenic compositions and methods
US6930101B1 (en) 1999-05-17 2005-08-16 The Regents Of The University Of California Thiazolopyrimidines useful as TNFα inhibitors
US6514948B1 (en) * 1999-07-02 2003-02-04 The Regents Of The University Of California Method for enhancing an immune response
WO2001012223A2 (fr) 1999-08-19 2001-02-22 Dynavax Technologies Corporation Procedes de modulation d'une reponse immunitaire par utilisation de sequences immunostimulantes et compositions utilisees
EP1221955B9 (fr) * 1999-09-25 2005-11-30 University Of Iowa Research Foundation Acides nucleiques immunostimulateurs
EP1322655B1 (fr) * 2000-01-14 2007-11-14 The Government of the United States of America, as represented by the Secretary of the Department of Health and Human Services Oligonucleotide synthetique et son utilisation pour induire une reaction immunitaire
AU2001231245A1 (en) * 2000-01-31 2001-08-07 The Regents Of The University Of California Immunomodulatory polynucleotides in treatment of an infection by an intracellular pathogen
US7585847B2 (en) * 2000-02-03 2009-09-08 Coley Pharmaceutical Group, Inc. Immunostimulatory nucleic acids for the treatment of asthma and allergy
AU4175101A (en) * 2000-02-23 2001-09-03 Univ California Method for treating inflammatory bowel disease and other forms of gastrointestinal inflammation
US20020028784A1 (en) 2000-03-10 2002-03-07 Nest Gary Van Methods of preventing and treating viral infections using immunomodulatory polynucleotide sequences
US20020107212A1 (en) 2000-03-10 2002-08-08 Nest Gary Van Methods of reducing papillomavirus infection using immunomodulatory polynucleotide sequences
US7129222B2 (en) * 2000-03-10 2006-10-31 Dynavax Technologies Corporation Immunomodulatory formulations and methods for use thereof
US20020098199A1 (en) * 2000-03-10 2002-07-25 Gary Van Nest Methods of suppressing hepatitis virus infection using immunomodulatory polynucleotide sequences
US7157437B2 (en) * 2000-03-10 2007-01-02 Dynavax Technologies Corporation Methods of ameliorating symptoms of herpes infection using immunomodulatory polynucleotide sequences
US20010046967A1 (en) * 2000-03-10 2001-11-29 Gary Van Nest Methods of preventing and treating respiratory viral infection using immunomodulatory polynucleotide
US20030129251A1 (en) * 2000-03-10 2003-07-10 Gary Van Nest Biodegradable immunomodulatory formulations and methods for use thereof
US6534062B2 (en) * 2000-03-28 2003-03-18 The Regents Of The University Of California Methods for increasing a cytotoxic T lymphocyte response in vivo
AU2001251407A1 (en) 2000-04-07 2001-10-23 The Regents Of The University Of California Synergistic improvements to polynucleotide vaccines
US6893821B2 (en) * 2000-05-05 2005-05-17 The Regents Of The University Of California Agents that modulate DNA-PK activity and methods of use thereof
US6689353B1 (en) * 2000-06-28 2004-02-10 Bayer Pharmaceuticals Corporation Stabilized interleukin 2
DE60142410D1 (de) 2000-12-27 2010-07-29 Dynavax Tech Corp Immunomodulatorische polynukleotide und verfahren zur deren verwendung
US20040132677A1 (en) * 2001-06-21 2004-07-08 Fearon Karen L. Chimeric immunomodulatory compounds and methods of using the same-IV
US7785610B2 (en) * 2001-06-21 2010-08-31 Dynavax Technologies Corporation Chimeric immunomodulatory compounds and methods of using the same—III
EP1420829A4 (fr) * 2001-08-07 2006-05-17 Dynavax Tech Corp Compositions immunomodulatrices, preparations, et leurs procedes d'utilisation
US7514414B2 (en) * 2001-09-24 2009-04-07 The United States Of America As Represented By The Department Of Health And Human Services Suppressors of CpG oligonucleotides and methods of use
CA2469082A1 (fr) * 2001-12-04 2003-06-12 Raj K. Puri Molecule chimerique destinee au traitement de troubles a mediation par cytokine de type th2
US7615227B2 (en) * 2001-12-20 2009-11-10 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Use of CpG oligodeoxynucleotides to induce angiogenesis
US7576066B2 (en) * 2002-07-03 2009-08-18 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
US7569553B2 (en) * 2002-07-03 2009-08-04 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
US7605138B2 (en) * 2002-07-03 2009-10-20 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
KR20050052467A (ko) 2002-08-12 2005-06-02 다이나박스 테크놀로지 코퍼레이션 면역조절 조성물, 이의 제조방법 및 이의 이용방법
DK1572095T3 (en) * 2002-09-13 2015-09-14 Novartis Ag BETA-L-2'-DEOXYNUCLEOTIDES FOR TREATMENT OF RESISTANT HBV STANDS AND COMBINATION THERAPIES
JP2006516099A (ja) * 2002-12-23 2006-06-22 ダイナバックス テクノロジーズ コーポレイション 分枝状の免疫調節化合物及び該化合物の使用方法
CN100546998C (zh) * 2002-12-23 2009-10-07 戴纳伐克斯技术股份有限公司 免疫刺激序列寡核苷酸和使用方法
CA2536139A1 (fr) * 2003-09-25 2005-04-07 Coley Pharmaceutical Group, Inc. Conjugues lipophiles d'acides nucleiques
CA2578775C (fr) * 2004-09-01 2016-05-03 Dynavax Technologies Corporation Procedes et compositions permettant d'inhiber des reponses immunitaires innees et auto-immunite correspondante
MY159370A (en) * 2004-10-20 2016-12-30 Coley Pharm Group Inc Semi-soft-class immunostimulatory oligonucleotides
CA2591582A1 (fr) * 2004-12-17 2006-06-22 Dynavax Technologies Corporation Methodes et compositions permettant d'induire ou de stimuler la tolerance immunitaire
EP2007421A2 (fr) * 2005-03-04 2008-12-31 Dynavax Technologies Corporation Vaccins comprenant des oligonucleotides immunostimulateurs (iss), desquels iss sont conjugues a des antigenes et stabilises dans des conditions de tampon et par d'autres excipients
JP5727367B2 (ja) * 2008-05-15 2015-06-03 ダイナバックス テクノロジーズ コーポレイション 免疫賦活オリゴヌクレオチドを使用する長期疾患改良
US20120177701A1 (en) * 2010-12-31 2012-07-12 Selecta Biosciences, Inc. Compositions comprising immunostimulatory nucleic acids and related methods

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6251678B1 (en) * 1999-02-05 2001-06-26 Merck & Co., Inc. Human papillomavirus vaccine formulations
WO2001015726A2 (fr) * 1999-08-27 2001-03-08 Inex Pharmaceuticals Corp. Compositions stimulant la secretion de cytokine et provoquant une reaction immunitaire
WO2001035991A2 (fr) * 1999-11-15 2001-05-25 Dynavax Technologies Corporation Compositions immunomodulatrices contenant une sequence immunostimulante liee a un antigene et procedes d'utilisation
WO2003000922A2 (fr) * 2001-06-21 2003-01-03 Dynavax Technologies Corporation Composes immunomodulateurs chimeriques et leurs procedes d'utilisation
WO2003106644A2 (fr) * 2002-06-14 2003-12-24 Medimmune, Inc. Formulations d'anticorps anti-virus syncytial respiratoire (rsv) stabilisees
WO2004060396A2 (fr) * 2002-12-27 2004-07-22 Chiron Corporation Immunogenes contenant des compositions de phospholipide

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
SIMONS ET AL: "Selective immune redirection in humans with ragweed allergy by injecting Amb a 1 linked to immunostimulatory DNA", JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, MOSBY - YEARLY BOOK, INC, US, vol. 113, no. 6, June 2004 (2004-06-01), pages 1144 - 1151, XP005396559, ISSN: 0091-6749 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE45196E1 (en) 2005-03-04 2014-10-14 Dynavax Technologies Corporation Compositions comprising structurally stable conjugate molecules
US8252757B2 (en) 2006-11-09 2012-08-28 Dynavax Technologies Corporation Long term disease modification using immunostimulatory oligonucleotides
US8815817B2 (en) 2008-05-15 2014-08-26 Dynavax Technologies Corporation Long term disease modification using immunostimulatory oligonucleotides
US9333254B2 (en) 2008-05-15 2016-05-10 Dynavax Technologies Corporation Long term disease modification using immunostimulatory oligonucleotides

Also Published As

Publication number Publication date
KR20070110901A (ko) 2007-11-20
JP2008531722A (ja) 2008-08-14
CA2600036A1 (fr) 2006-09-14
US7718622B2 (en) 2010-05-18
CN101171033A (zh) 2008-04-30
USRE45196E1 (en) 2014-10-14
AU2006220835A1 (en) 2006-09-14
EP2007421A2 (fr) 2008-12-31
US20070036807A1 (en) 2007-02-15
AU2006220835B2 (en) 2012-01-19
NZ561144A (en) 2009-09-25
SG160336A1 (en) 2010-04-29
WO2006096497A2 (fr) 2006-09-14

Similar Documents

Publication Publication Date Title
WO2006096497A3 (fr) Compositions contenant des molecules conjuguees structurellement stables
WO2006067632A3 (fr) Vaccins à base de conjugués de saccharide
WO2001035991A3 (fr) Compositions immunomodulatrices contenant une sequence immunostimulante liee a un antigene et procedes d'utilisation
WO2000062800A3 (fr) Vaccins
BRPI0417341A (pt) fator ix glicopeguilado
MA30066B1 (fr) Vaccin
EA200801935A1 (ru) Конъюгатные вакцины
DK2343320T3 (da) Anti-gitr-antistoffer og anvendelser deraf
NO20031646L (no) Adjuvanssammensetning omfattende et immunostimulatorisk oligonukleotid og en tokol
MX2009001412A (es) Vacunas de matriz de proteinas y metodos de hacer y administrar tales vacunas.
CY1112763T1 (el) Υπο-ακετυλιωμενα και υπερ-ακετυλιωμενα μηνιγγοκοκκικα καψικα σακχαριδια
WO2005097211A3 (fr) Compositions adjuvantes ameliorant la reponse immunitaire a des vaccins et methodes d'utilisation
WO2002080965A3 (fr) Composition vaccinale
WO2006127896A3 (fr) Facteur ix glycopegyle
WO2006034292A3 (fr) Anticorps dirige contre le virus respiratoire syncytial et procedes de production de vaccins associes
WO2006113214A3 (fr) Vaccin contre des souches pandemiques des virus de la grippe
WO2010141312A3 (fr) Protéines de fusion flagelline et conjugués comprenant des antigènes pneumocoques et leurs procédés d'utilisation
WO2010146598A3 (fr) Vaccin de rotavirus sec et stable, compositions et procédé de préparation de ce dernier
WO2003051392A3 (fr) Vaccin
WO2009080764A3 (fr) Administration orale ou nasale de composés comprenant des séquences d'acides aminés
WO2005007673A3 (fr) Peptides immunogenes
WO2003025119A3 (fr) Compositions contenant des oligonucleotides immunostimulants et leurs utilisations pour amplifier des immunotherapies declenchees indirectement par le recepteur fc
CN111615400A (zh) 作为治疗工具的精确糖缀合物
WO2007041216A3 (fr) Antigenes du plasmodium en phase hepatique
WO2005000884A8 (fr) Conjugues d'acide poly-gamma-glutamique pour solliciter des reponses immunitaires dirigees contre des bacilles

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200680015107.7

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: 2006220835

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2007558260

Country of ref document: JP

Ref document number: 561144

Country of ref document: NZ

ENP Entry into the national phase

Ref document number: 2600036

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2006220835

Country of ref document: AU

Date of ref document: 20060303

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2006736828

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: RU

WWE Wipo information: entry into national phase

Ref document number: 1020077022686

Country of ref document: KR

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 06736828

Country of ref document: EP

Kind code of ref document: A2